Exisulind (BioDeep_00000783884)

   


代谢物信息卡片


Sulindac sulfone

化学式: C20H17FO4S (372.0831534)
中文名称: 舒林酸砜
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC1=C(C2=C(C1=CC3=CC=C(C=C3)S(=O)(=O)C)C=CC(=C2)F)CC(=O)O
InChI: InChI=1S/C20H17FO4S/c1-12-17(9-13-3-6-15(7-4-13)26(2,24)25)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9-

描述信息

D018501 - Antirheumatic Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D016861 - Cyclooxygenase Inhibitors
C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor > C2127 - cGMP Phosphodiesterase Inhibitor
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents
D020011 - Protective Agents > D016588 - Anticarcinogenic Agents
D002491 - Central Nervous System Agents > D000700 - Analgesics
D000893 - Anti-Inflammatory Agents
D000970 - Antineoplastic Agents
D004791 - Enzyme Inhibitors

同义名列表

2 个代谢物同义名

Sulindac sulfone; Exisulind



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Yong-Jun Tang, Kai Hu, Wei-Hua Huang, Chong-Zhi Wang, Zhi Liu, Yao Chen, Dong-Sheng Ouyang, Zhi-Rong Tan, Hong-Hao Zhou, Chun-Su Yuan. Effects of FMO3 Polymorphisms on Pharmacokinetics of Sulindac in Chinese Healthy Male Volunteers. BioMed research international. 2017; 2017(?):4189678. doi: 10.1155/2017/4189678. [PMID: 28331852]
  • Hsin-Hsiung Tai, Xiuling Chi, Min Tong. Regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by non-steroidal anti-inflammatory drugs (NSAIDs). Prostaglandins & other lipid mediators. 2011 Nov; 96(1-4):37-40. doi: 10.1016/j.prostaglandins.2011.06.005. [PMID: 21763448]
  • Fernando Santos, Lígia Teixeira, Marlene Lúcio, Helena Ferreira, Diana Gaspar, José L F C Lima, Salette Reis. Interactions of sulindac and its metabolites with phospholipid membranes: an explanation for the peroxidation protective effect of the bioactive metabolite. Free radical research. 2008 Jul; 42(7):639-50. doi: 10.1080/10715760802270326. [PMID: 18654879]
  • Bhagavathi A Narayanan, Bandaru S Reddy, Maarten C Bosland, Dominick Nargi, Lori Horton, Carla Randolph, Narayanan K Narayanan. Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Oct; 13(19):5965-73. doi: 10.1158/1078-0432.ccr-07-0744. [PMID: 17908994]
  • I M Kapetanovic, R Krishnaraj, T Martin-Jimenez, L Yuan, R B van Breemen, A Lyubimov. Effects of oral dosing paradigms (gavage versus diet) on pharmacokinetics and pharmacodynamics. Chemico-biological interactions. 2006 Dec; 164(1-2):68-75. doi: 10.1016/j.cbi.2006.08.019. [PMID: 17027946]
  • Virginie Quidville, Nadine Segond, Sylvie Lausson, Melinee Frenkian, Regis Cohen, Annick Jullienne. 15-Hydroxyprostaglandin-dehydrogenase is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a human medullary thyroid carcinoma cell line. Prostaglandins & other lipid mediators. 2006 Oct; 81(1-2):14-30. doi: 10.1016/j.prostaglandins.2006.06.004. [PMID: 16997128]
  • Yen-Ling Chen, Yuh-Jyh Jong, Shou-Mei Wu. Capillary electrophoresis combining field-amplified sample stacking and electroosmotic flow suppressant for analysis of sulindac and its two metabolites in plasma. Journal of chromatography. A. 2006 Jun; 1119(1-2):176-82. doi: 10.1016/j.chroma.2006.02.054. [PMID: 16530777]
  • Samir E Witta, Daniel L Gustafson, A Scott Pierson, Alexander Menter, Scott N Holden, Michele Basche, Martha Persky, Cindy L O'Bryant, Chan Zeng, Anna Baron, Michael E Long, Amy Gibbs, Karen Kelly, Paul A Bunn, Daniel C Chan, Patrick Pallansch, S Gail Eckhardt. A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Nov; 10(21):7229-37. doi: 10.1158/1078-0432.ccr-03-0181. [PMID: 15534096]
  • Piotr Skopinski, Jerzy Szaflik, Barbara Duda-Król, Jadwiga Nartowska, Ewa Sommer, Joanna Chorostowska-Wynimko, Urszula Demkow, Ewa Skopinska-Rózewska. Suppression of angiogenic activity of sera from diabetic patients with non-proliferative retinopathy by compounds of herbal origin and sulindac sulfone. International journal of molecular medicine. 2004 Oct; 14(4):707-11. doi: 10.3892/ijmm.14.4.707. [PMID: 15375605]
  • Daniel J Berg, Juan Zhang, Joel V Weinstock, Hanan F Ismail, Keith A Earle, Hector Alila, Rifat Pamukcu, Steven Moore, Richard G Lynch. Rapid development of colitis in NSAID-treated IL-10-deficient mice. Gastroenterology. 2002 Nov; 123(5):1527-42. doi: 10.1053/gast.2002.1231527. [PMID: 12404228]
  • M Oshima, N Murai, S Kargman, M Arguello, P Luk, E Kwong, M M Taketo, J F Evans. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer research. 2001 Feb; 61(4):1733-40. doi: . [PMID: 11245490]
  • R van Stolk, G Stoner, W L Hayton, K Chan, B DeYoung, L Kresty, B H Kemmenoe, P Elson, L Rybicki, J Church, K Provencher, D McLain, E Hawk, B Fryer, G Kelloff, R Ganapathi, G T Budd. Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000 Jan; 6(1):78-89. doi: NULL. [PMID: 10656435]
  • G A Piazza, D S Alberts, L J Hixson, N S Paranka, H Li, T Finn, C Bogert, J M Guillen, K Brendel, P H Gross, G Sperl, J Ritchie, R W Burt, L Ellsworth, D J Ahnen, R Pamukcu. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer research. 1997 Jul; 57(14):2909-15. doi: . [PMID: 9230200]
  • G F Ray, R C Lanman, C J Fu, N S Paranka, R Pamukcu, S C Wheeler. Determination of FGN-1 (an active metabolite of sulindac) in human plasma, urine, and feces by HPLC. Journal of pharmaceutical and biomedical analysis. 1995 Dec; 14(1-2):213-20. doi: 10.1016/0731-7085(95)01631-7. [PMID: 8833984]
  • M Siluveru, J T Stewart. Determination of sulindac and its metabolites in human serum by reversed-phase high-performance liquid chromatography using on-line post-column ultraviolet irradiation and fluorescence detection. Journal of chromatography. B, Biomedical applications. 1995 Nov; 673(1):91-6. doi: 10.1016/0378-4347(95)00239-f. [PMID: 8925079]
  • W R Ravis, C J Diskin, K D Campagna, C R Clark, C L McMillian. Pharmacokinetics and dialyzability of sulindac and metabolites in patients with end-stage renal failure. Journal of clinical pharmacology. 1993 Jun; 33(6):527-34. doi: 10.1002/j.1552-4604.1993.tb04699.x. [PMID: 8366178]
  • T P Gibson, M R Dobrinska, J H Lin, L A Entwistle, R O Davies. Biotransformation of sulindac in end-stage renal disease. Clinical pharmacology and therapeutics. 1987 Jul; 42(1):82-8. doi: 10.1038/clpt.1987.112. [PMID: 3595070]
  • N Grgurinovich. High-performance liquid chromatography of sulindac and its sulphone and sulphide metabolites in plasma. Journal of chromatography. 1987 Feb; 414(1):211-6. doi: 10.1016/0378-4347(87)80043-9. [PMID: 3571386]
  • N Bayley, R W Warne, R F Moulds, R W Bury. A kinetic study of sulindac in the elderly. Australian and New Zealand journal of medicine. 1987 Feb; 17(1):39-42. doi: 10.1111/j.1445-5994.1987.tb05047.x. [PMID: 3476045]
  • H A Strong, N J Warner, A G Renwick, C F George. Sulindac metabolism: the importance of an intact colon. Clinical pharmacology and therapeutics. 1985 Oct; 38(4):387-93. doi: 10.1038/clpt.1985.192. [PMID: 4042521]
  • J H Lin, K C Yeh, D E Duggan. Effect of uremia and anephric state on the pharmacokinetics of sulindac and its metabolites in rats. I. An application of pharmacokinetic model for reversible metabolism. Drug metabolism and disposition: the biological fate of chemicals. 1985 Sep; 13(5):602-7. doi: NULL. [PMID: 2865111]
  • J H Lin, K C Yeh, D E Duggan. Effect of uremia and anephric state on the pharmacokinetics of sulindac and its metabolites in rats. II. Differential effects on the biliary excretion. Drug metabolism and disposition: the biological fate of chemicals. 1985 Sep; 13(5):608-13. doi: NULL. [PMID: 2865112]
  • D S Sitar, J A Owen, B MacDougall, T Hunter, P A Mitenko. Effects of age and disease on the pharmacokinetics and pharmacodynamics of sulindac. Clinical pharmacology and therapeutics. 1985 Aug; 38(2):228-34. doi: 10.1038/clpt.1985.163. [PMID: 4017423]
  • M R Dobrinska, D E Furst, T Spiegel, W C Vincek, R Tompkins, D E Duggan, R O Davies, H E Paulus. Biliary secretion of sulindac and metabolites in man. Biopharmaceutics & drug disposition. 1983 Oct; 4(4):347-58. doi: 10.1002/bdd.2510040407. [PMID: 6661513]
  • S Kitamura, K Tatsumi. In vitro metabolism of sulindac and sulindac sulfide: enzymatic formation of sulfoxide and sulfone. Japanese journal of pharmacology. 1982 Oct; 32(5):833-8. doi: 10.1254/jjp.32.833. [PMID: 7176218]
  • B N Swanson, P Mojaverian, V K Boppana, M R Dudash. Effect of dimethyl sulfoxide on sulindac disposition in rats. Drug metabolism and disposition: the biological fate of chemicals. 1981 Nov; 9(6):499-502. doi: NULL. [PMID: 6120805]